EcoDrugPlus

Cytidine Deaminase

Ensembl ID : ENSGGOG00000004033
Gene Symbol: CDA
2 Cross references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 11 Subfamily B Member 2

Ensembl ID : ENSGGOG00000007547
Gene Symbol: CYP11B2
2 Cross references
42 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 17 Subfamily A Member 1

Ensembl ID : ENSGGOG00000012438
Gene Symbol: CYP17A1
2 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSGGOG00000014029
Gene Symbol: CYP19A1
2 Cross references
315 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSGGOG00000009114
Gene Symbol: CYP26A1
2 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 3 Subfamily A Member 4

Ensembl ID : ENSGGOG00000003894
Gene Symbol: CYP3A4
2 Cross references
637 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 3 Subfamily A Member 43

Ensembl ID : ENSGGOG00000002076
Gene Symbol: CYP3A43
2 Cross references
636 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 3 Subfamily A Member 5

Ensembl ID : ENSGGOG00000003875
Gene Symbol: CYP3A5
2 Cross references
643 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 46 Subfamily A Member 1

Ensembl ID : ENSGGOG00000004816
Gene Symbol: CYP46A1
2 Cross references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSGGOG00000028476
Gene Symbol: DGAT1
2 Cross references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dihydrofolate Reductase

Ensembl ID : ENSGGOG00000022366
Gene Symbol: DHFR
2 Cross references
325 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dipeptidyl Peptidase 4

Ensembl ID : ENSGGOG00000005778
Gene Symbol: DPP4
2 Cross references
282 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).